Medios AG (ILM1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medios AG (ILM1) has a cash flow conversion efficiency ratio of -0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.50 Million ≈ $-2.92 Million USD) by net assets (€514.22 Million ≈ $601.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medios AG - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Medios AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Medios AG for a breakdown of total debt and financial obligations.
Medios AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medios AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Malacca Bhd
KLSE:2593
|
0.088x |
|
Yunnan Bowin Technology Industry Co Ltd
SHG:600883
|
-0.001x |
|
Xinjiang Youhao Group Co Ltd
SHG:600778
|
0.281x |
|
AerSale Corp
NASDAQ:ASLE
|
0.027x |
|
CellaVision AB
ST:CEVI
|
0.058x |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
0.000x |
|
Know Labs Inc.
NYSE MKT:KNW
|
0.269x |
|
Canada Nickel Company Inc
V:CNC
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Medios AG (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medios AG from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Medios AG (ILM1) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €514.22 Million ≈ $601.18 Million |
€43.00 Million ≈ $50.27 Million |
0.084x | -42.08% |
| 2024-12-31 | €510.19 Million ≈ $596.47 Million |
€73.67 Million ≈ $86.12 Million |
0.144x | +312.59% |
| 2023-12-31 | €468.81 Million ≈ $548.08 Million |
€16.41 Million ≈ $19.18 Million |
0.035x | -57.76% |
| 2022-12-31 | €448.05 Million ≈ $523.81 Million |
€37.12 Million ≈ $43.40 Million |
0.083x | -46.92% |
| 2021-12-31 | €394.16 Million ≈ $460.82 Million |
€61.52 Million ≈ $71.92 Million |
0.156x | +158.32% |
| 2020-12-31 | €142.43 Million ≈ $166.51 Million |
€-38.12 Million ≈ $-44.56 Million |
-0.268x | -4762.04% |
| 2019-12-31 | €81.63 Million ≈ $95.43 Million |
€-449.29K ≈ $-525.26K |
-0.006x | +87.62% |
| 2018-12-31 | €70.50 Million ≈ $82.42 Million |
€-3.14 Million ≈ $-3.67 Million |
-0.044x | -348.97% |
| 2017-12-31 | €45.68 Million ≈ $53.40 Million |
€816.00K ≈ $953.99K |
0.018x | +138.51% |
| 2016-12-31 | €34.10 Million ≈ $39.86 Million |
€-1.58 Million ≈ $-1.85 Million |
-0.046x | +84.92% |
| 2015-12-31 | €323.78K ≈ $378.53K |
€-99.64K ≈ $-116.49K |
-0.308x | -- |
| 2014-12-31 | €0.00 ≈ $0.00 |
€13.30K ≈ $15.55K |
x | -- |
| 2013-12-31 | €7.81K ≈ $9.13K |
€103.36K ≈ $120.84K |
13.241x | +10691.51% |
| 2012-12-31 | €172.97K ≈ $202.22K |
€21.22K ≈ $24.81K |
0.123x | +157.35% |
| 2011-12-31 | €376.75K ≈ $440.46K |
€-80.60K ≈ $-94.23K |
-0.214x | -1872.06% |
| 2010-12-31 | €341.07K ≈ $398.75K |
€-3.70K ≈ $-4.33K |
-0.011x | -- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. The company operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic preparations, antibody therapies, a… Read more